A fossil record of zidovudine resistance in transmitted isolates of HIV-1
Open Access
- 20 November 2001
- journal article
- editorial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (24) , 13485-13487
- https://doi.org/10.1073/pnas.251559398
Abstract
The introduction of zidovudine (3′-azido-3′-deoxythymidine; AZT; Scheme S1) into clinical practice in 1987 ushered in the therapeutic era of the AIDS epidemic. Not long thereafter, isolation of an AZT-resistant variant of HIV type 1 (HIV-1) was reported (1). Work by several groups demonstrated the association between emergence of AZT resistance and disease progression in patients receiving antiretroviral therapy (2–4). High-level AZT resistance requires mutations at reverse transcriptase (RT) codons 41, 67, 70, 210, 215, and 219, which emerge in an ordered fashion (5, 6). The K70R mutation usually is the first to emerge. Although this mutation produces only a modest decrease in drug susceptibility, K70R mutants are selected rapidly after initiation of AZT (7). Subsequently, variants with mutations at codon 215 emerge and replace the K70R mutants. A likely explanation for the slower emergence of mutants carrying T215Y or F substitutions is the requirement for a double-nucleotide mutation at this codon [215T(ACC) to 215Y(TAC) or 215F(TTC), respectively]. Transmission of an AZT-resistant isolate of HIV-1 was first reported in 1992 (8). Recent studies show a prevalence of AZT resistance mutations in viral sequences from newly infected individuals of 5–10% (9, 10), documenting a dramatic increase in the transmission of AZT-resistant HIV-1 over the past decade. In the absence of continued selective pressure from AZT-containing therapy, resistant variants eventually are replaced by AZT-susceptible revertants. Such revertants frequently involve the substitution at codon 215 of unusual amino acids such as aspartate, asparagine, cysteine, or serine in place of the mutant and wild-type residues more commonly encountered at this position. The 215D(GAC), 215N(AAC), 215C(TGC), and 215S(TCC) variants can each arise as a result of single nucleotide changes from 215Y or -F and appear to be more common than wild-type …Keywords
This publication has 22 references indexed in Scilit:
- Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse TranscriptaseJournal of Virology, 2001
- Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant VirusJournal of Virology, 2001
- Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment with Zidovudine‐Lamivudine‐Ritonavir: Genotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from AIDS Clinical Trials Group Protocol 315The Journal of Infectious Diseases, 2000
- Phenotypic Mechanism of HIV-1 Resistance to 3‘-Azido-3‘-deoxythymidine (AZT): Increased Polymerization Processivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse TranscriptaseBiochemistry, 1998
- Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Does Not Adversely Affect Outcome at 1 YearThe Journal of Infectious Diseases, 1996
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS, 1996
- Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine TreatmentThe Journal of Infectious Diseases, 1995
- A Mutation in Human Immunodeficiency Virus Reverse Transcriptase and Decline in CD4 Lymphocyte Numbers in Long-Term Zidovudine RecipientsThe Journal of Infectious Diseases, 1993
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989